Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports

20-11-2023 | Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Global Cardiovascular Research: Gaps and Opportunities

Authors: Maha Inam, Zainab Samad, Elizabeth M. Vaughan, Aysha Almas, Bashir Hanif, Abdul Mannan Minhas, Zeerak Jarrar, Fatima Zohra Habib, Sana Sheikh, Dongshan Zhu, Salim S. Virani

Published in: Current Cardiology Reports

Login to get access

Abstract

Purpose of Review

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. CVDs contribute to a large health and economic burden on a global scale. We aim to describe the current landscape of global cardiovascular research, highlight significant findings, and identify potential opportunities for further studies.

Recent Findings

There has been remarkable research output regarding cardiovascular health in recent decades. Large-scale collaborative studies have made impactful strides in identifying modifiable risk factors and forming evidence-based guidelines to facilitate improved cardiovascular care and outcomes. However, there are significant CVD disparities between high- and low- income countries which require interventions to mitigate these inequalities.

Summary

Encouraging collaborative partnerships, strengthening research capacity in low-resource settings, and promoting equity in research are fundamental strategic approaches to help improve global cardiovascular research.
Literature
1.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1459–544. CrossRef
2.
•• Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982–3021. This study forms the prime resource which outlines the global magnitude of total CVD burden (incidence, prevalence, case fatality, mortality, health risks), identifies underlying causes of CVD death, and links them to relevant risk factors . PubMedPubMedCentralCrossRef
3.
4.
5.
Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016. Circulation. 2021;144(4):271–82. PubMedPubMedCentralCrossRef
6.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-621. PubMedCrossRef
7.
Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff Proj Hope. 2007;26(1):13–24. CrossRef
8.
Huffman MD, Baldridge A, Bloomfield GS, Colantonio LD, Prabhakaran P, Ajay VS, et al. Global cardiovascular research output, citations, and collaborations: a time-trend, bibliometric analysis (1999–2008). PLoS ONE. 2013;8(12):e83440. PubMedPubMedCentralCrossRef
9.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet Lond Engl. 2004;364(9438):937–52. CrossRef
10.
O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet Lond Engl. 2016;388(10046):761–75. CrossRef
11.
Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet Lond Engl. 2011;378(9798):1231–43. CrossRef
12.
Joseph P, Kutty VR, Mohan V, Kumar R, Mony P, Vijayakumar K, et al. Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. Eur Heart J. 2022;43(30):2831–40. PubMedCrossRef
13.
14.
15.
Liu J, Bu X, Wei L, Wang X, Lai L, Dong C, et al. Global burden of cardiovascular diseases attributable to hypertension in young adults from 1990 to 2019. J Hypertens. 2021;39(12):2488–96. PubMedCrossRef
16.
Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21(1):222. PubMedPubMedCentralCrossRef
17.
Wu S, Xu W, Guan C, Lv M, Jiang S, Jinhua Z. Global burden of cardiovascular disease attributable to metabolic risk factors, 1990–2019: an analysis of observational data from a 2019 Global Burden of Disease study. BMJ Open. 2023;13(5):e069397. PubMedPubMedCentralCrossRef
18.
Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71. PubMedCrossRef
19.
Dong C, Bu X, Liu J, Wei L, Ma A, Wang T. Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: a systematic analysis of the Global Burden of Disease study. Nutr Metab Cardiovasc Dis NMCD. 2022;32(4):897–907. PubMedCrossRef
20.
Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease and mortality in 155,722 individuals from 21 high-, middle-, and low-income countries. Lancet Lond Engl. 2020;395(10226):795–808. CrossRef
21.
• Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27. Findings from this study reveal significant metrics to compare CVD risk and events between LICs and HICs, suggesting a substantially highest risk of major CVD and death in LICs. The results highlight the disparity between these regions and identify a lack of implementation of evidence-based practice in LICs . PubMedCrossRef
22.
Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-43. PubMedPubMedCentralCrossRef
23.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-646. PubMedPubMedCentral
24.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. PubMedCrossRef
25.
Teo KK, Rafiq T. Cardiovascular risk factors and prevention: a perspective from developing countries. Can J Cardiol. 2021;37(5):733–43. PubMedCrossRef
26.
Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. Am J Med. 2011;124(2):95–102. PubMedCrossRef
27.
•• Qureshi NQ, Mufarrih SH, Bloomfield GS, Tariq W, Almas A, Mokdad AH, et al. Disparities in cardiovascular research output and disease outcomes among high-, middle- and low-income countries — an analysis of global cardiovascular publications over the last decade (2008–2017). Glob Heart. 2021;16(1):4. This study outlines global cardiovascular publications over the last decade according to country development indicators. The results reveal a distinct disparity in research output and CVD burden between LICs and HICs and identify an urgent need to strengthen research capacity within LICs to bridge this gap. PubMedPubMedCentralCrossRef
28.
29.
Abushouk AI, Sayed A, Ghanem E, Hassanin A, Mentias A, Bendary A, et al. Africa on the global stage: analyzing 30 years of African-led clinical trials in cardiovascular medicine. Circ Cardiovasc Qual Outcomes. 2023;16(9):e009895. PubMedCrossRef
30.
Mendis S, Yach D, Bengoa R, Narvaez D, Zhang X. Research gap in cardiovascular disease in developing countries. Lancet. 2003;361(9376):2246–7. PubMedCrossRef
31.
32.
Pascual-Leone N, Liu JW, Beschloss A, Chenna SS, Saifi C. The language of all medical publications and spine publications from 1950 to 2020. North Am Spine Soc J. 2022;21(10):100118.
33.
34.
Ransing R, Vadivel R, Halabi SE, Jatchavala C, Shalbafan M, Noël C, et al. Language as multi-level barrier in health research and the way forward. Indian J Psychol Med. 2023;45(1):65–8. PubMedCrossRef
35.
Pearson TA. Cardiovascular disease in developing countries: myths, realities, and opportunities. Cardiovasc Drugs Ther. 1999;13(2):95–104. PubMedCrossRef
36.
37.
38.
Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries — a systematic review. Int J Equity Health. 2018;17(1):37. PubMedPubMedCentralCrossRef
39.
40.
Pena MSB, Bloomfield GS. Cardiovascular disease research and the development agenda in low- and middle-income countries. Glob Heart. 2015;10(1):71–3. CrossRef
41.
42.
43.
Islam MM. Social determinants of health and related inequalities: confusion and implications. Front Public Health. 2019;8(7):11. CrossRef
44.
Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, et al. Social determinants of cardiovascular disease. Circ Res. 2022;130(5):782–99. PubMedPubMedCentralCrossRef
45.
Mannoh I, Hussien M, Commodore-Mensah Y, Michos ED. Impact of social determinants of health on cardiovascular disease prevention. Curr Opin Cardiol. 2021;36(5):572–9. PubMedCrossRef
46.
Angell SY, McConnell MV, Anderson CAM, Bibbins-Domingo K, Boyle DS, Capewell S, et al. The American Heart Association 2030 impact goal: a presidential advisory from the American Heart Association. Circulation. 2020;141(9):e120–38. PubMedPubMedCentralCrossRef
47.
Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18(1):975. PubMedPubMedCentralCrossRef
48.
McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e44-54. PubMedCrossRef
Metadata
Title
Global Cardiovascular Research: Gaps and Opportunities
Authors
Maha Inam
Zainab Samad
Elizabeth M. Vaughan
Aysha Almas
Bashir Hanif
Abdul Mannan Minhas
Zeerak Jarrar
Fatima Zohra Habib
Sana Sheikh
Dongshan Zhu
Salim S. Virani
Publication date
20-11-2023
Publisher
Springer US
Published in
Current Cardiology Reports
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01996-2
Webinar | 16-05-2023 | 17:30 (CET)

Keynote Webinar | Spotlight on Cardio-Oncology

Watch now

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández
Image Credits